视网膜药物市场规模、份额和成长分析（按成分、适应症、剂型、通路和地区划分）－2026-2033年产业预测

预计到 2024 年，全球视网膜治疗市场规模将达到 218.6 亿美元，到 2025 年将达到 236.5 亿美元，到 2033 年将达到 444.2 亿美元，预测期（2026-2033 年）的复合年增长率为 8.2%。

由于全球视网膜疾病（尤其是老龄化黄斑部病变(AMD)、糖尿病视网膜病变和视网膜静脉阻塞 (RVO)）的盛行率不断上升，视网膜治疗市场正经历显着增长。这些疾病影响着全球数百万人的健康。人口老化、糖尿病患者数量的增加以及眼科诊断和治疗可近性的提高，都在推动市场扩张。抗 VEGF 疗法，特别是 aflavercept、ranibizumab 和 brolucizumab，是主导市场收入成长的主要因素，其中 aflavercept 的销售额尤为突出。缓释给药系统和基因疗法等创新技术正在革新治疗方法，有效解决慢性病患者难以坚持注射频率等难题。主要企业正致力于开发更持久的治疗方法、双重抑制策略和先进的玻璃体内植入，进而为视网膜疾病的治疗带来更有效的未来。

全球视网膜治疗市场按药物类别、适应症、製剂形式、用途、通路和地区细分。依药物类别划分，可分为抗血管内皮生长因子（VEGF）药物、皮质类固醇、免疫调节剂、基因及细胞疗法、小分子疗法及其他。依适应症划分，可分为老龄化黄斑部病变、糖尿病视网膜病变、葡萄膜炎等。依剂型划分，可分为注射剂、植入、眼药水、口服药锭/胶囊及软膏/凝胶。依通路划分，可分为医院药房、零售药房和线上药房。按地区划分，可分为北美、欧洲、亚太、中东和非洲以及拉丁美洲。

推动全球视网膜治疗市场发展的因素

视网膜疾病（例如老龄化黄斑部病变(AMD)、糖尿病视网膜病变 (DR) 和视网膜静脉阻塞 (RVO)）的快速成长是全球视网膜治疗市场的主要驱动力。这些疾病影响数百万患者，且盛行率持续上升，导致大量患者亟需有效的视网膜治疗方法。人口老化、糖尿病发病率上升、不良饮食习惯以及萤幕使用时间增加等因素共同加剧了视网膜健康问题，从而推动了对创新疗法的需求。眼科医疗服务的可近性提高也增强了人们对这些疾病的认识，进而推动了对介入疗法（例如抗 VEGF 药物、皮质类固醇和先进基因疗法）的需求。

限制全球视网膜治疗市场发展的因素

全球视网膜治疗市场面临许多限制因素，其中视网膜治疗费用高昂尤为突出，严重限制了患者的可及性，尤其是在中低收入地区。治疗多种视网膜疾病所必需的标准抗VEGF药物，其价格往往超出许多患者的承受能力。儘管存在一些生物相似药可供选择，但对许多医疗系统和个人而言，这些药物仍然是一项巨大的经济挑战。此外，长期治疗方案会加重病患和医疗服务提供者的经济负担。开发中国家的许多公共医疗系统难以承担这些治疗方法的资金筹措，而私人保险计划往往限制承保范围或收取高额自付费用，从而阻碍患者坚持治疗。

全球视网膜药物市场趋势

全球视网膜治疗市场正经历着向基因疗法的重大转变，预计将彻底改变目前缺乏有效治疗方案的遗传性视网膜疾病的治疗现况。这种创新方法专注于利用腺结合病毒（AAV）的载体实现持久的治疗效果，从而实现抗血管内皮生长因子（VEGF）的持续表达。主要市场参与者正在推进有前景的候选药物的研发，特别是那些针对罕见视网膜营养不良的药物，从而提升了这些治疗方法的战略价值。获得孤儿药资格认定的吸引力，加上单剂量给药的潜力以及强有力的定价策略，巩固了基因疗法作为未来视网膜治疗领域核心组成部分的地位，并推动了相关投资和研究的倡议。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 价值链分析
• 监管机构
• 研发线产品分析
• 案例研究

全球视网膜药物市场规模（按药物类别和复合年增长率划分）（2026-2033 年）

• 抗 VEGF 药物
  • VEGF-A拮抗剂
  • 双标靶抗血管新生药物
• 皮质类固醇
  • 玻璃体内植入
  • 注射用悬浮液
• 免疫调节剂
• 基因和细胞疗法
• 小分子疗法
• 其他药物类别

全球视网膜药物市场规模（按适应症和复合年增长率划分）（2026-2033 年）

• 老龄化黄斑部病变
• 糖尿病视网膜病变
• 葡萄膜炎
• 其他的

全球视网膜药物市场规模（依剂型及复合年增长率划分）（2026-2033 年）

• 注射（溶液、混悬液）
• 植入（可生物降解、不可生物降解）
• 眼药水
• 口服片剂/胶囊
• 软膏和凝胶

全球视网膜药物市场规模（依分销管道划分）及复合年增长率（2026-2033 年）

• 医院药房
• 零售药房
• 网路药房

全球视网膜药物市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Roche Holding AG（incl. Genentech）
• Regeneron Pharmaceuticals, Inc.
• Novartis AG
• Bayer AG
• Allergan（AbbVie Inc.）
• Alcon Inc.
• Santen Pharmaceutical Co., Ltd.
• MeiraGTx Holdings plc
• Ocuphire Pharma, Inc.
• Kodiak Sciences Inc.
• Adverum Biotechnologies, Inc.
• Oxurion NV
• Graybug Vision, Inc.
• Clearside Biomedical, Inc.
• Outlook Therapeutics, Inc.
• Iveric Bio（acquired by Astellas Pharma）
• Sandoz（a Novartis spin-off for biosimilars）
• Coherus BioSciences, Inc.
• Biogen Inc.

结论与建议

Global Retinal Drugs Market size was valued at USD 21.86 Billion in 2024 and is poised to grow from USD 23.65 Billion in 2025 to USD 44.42 Billion by 2033, growing at a CAGR of 8.2% during the forecast period (2026-2033).

The global retinal drugs market is experiencing significant growth driven by the increasing prevalence of retinal diseases such as age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion (RVO), which collectively affect millions globally. The ageing population and rising diabetes rates, alongside improved access to ophthalmic diagnostics and therapies, are propelling market expansion. Anti-VEGF treatments, particularly aflibercept, ranibizumab, and brolucizumab, dominate market revenue, with aflibercept leading sales. Innovations such as sustained-release drug delivery systems and gene therapies are revolutionizing treatment approaches, addressing challenges like injection frequency compliance in chronic conditions. Key players are focusing on developing longer-lasting therapies, dual-inhibition strategies, and advanced intravitreal implants, shaping a more effective future for retinal disease management.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Retinal Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Retinal Drugs Market Segments Analysis

The global Retinal Drugs market is segmented on the basis of Drug Classes, Indication, Formulation, Application, Distribution Channel and region. By Drug Classes, the market is segmented into Anti-VEGF Agents, Corticosteroids, Immunomodulators, Gene & Cell Therapies, Small Molecule Therapies, and Others. By Indication, the market is segmented into Macular Degeneration, Diabetic Retinopathy, Uveitis, and Others. Based on Formulation, the market is segmented into Injectables, Implants, Eye Drops, Oral Tablets/Capsules, and Ointments & Gels. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. By region, the market is segmented into North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America.

Driver of the Global Retinal Drugs Market

The rapid rise in retinal diseases such as age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinal vein occlusion (RVO) significantly propels the expansion of the global retinal drugs market. With millions affected by these conditions and their prevalence steadily increasing, a large patient base is seeking effective retinal therapies. Contributing factors such as aging populations, diabetes prevalence, poor dietary habits, and heightened screen time have compounded the issues related to retinal health, leading to a greater demand for innovative treatments. Improved access to eye care has also heightened awareness of these diseases, increasing the need for interventions like anti-VEGF medications, corticosteroids, and advanced gene therapies.

Restraints in the Global Retinal Drugs Market

The Global Retinal Drugs market faces substantial constraints due to the prohibitive costs associated with retinal treatments, which severely limit accessibility, especially in low- and middle-income regions. The standard anti-VEGF medications, essential for treating various retinal conditions, are often priced at levels that many patients cannot afford. Although some biosimilar options exist, they still represent a financial challenge for numerous healthcare systems and individuals. Furthermore, the long durations of treatment regimens can exacerbate the economic burden on patients and healthcare providers alike. Many public healthcare systems in developing nations struggle to fund or reimburse these therapies, while private insurance plans frequently restrict coverage or impose high copays, discouraging patient compliance.

Market Trends of the Global Retinal Drugs Market

The Global Retinal Drugs market is witnessing a significant shift towards gene therapy, which is poised to revolutionize treatment for inherited retinal diseases lacking effective solutions. This innovative approach focuses on delivering long-lasting therapeutic effects through AAV-based vectors, enabling sustained anti-VEGF expression. Prominent market players are advancing promising candidates, particularly for rare retinal dystrophies, thereby enhancing the strategic value of these therapies. The allure of orphan drug designations, coupled with the potential for one-time dosing and robust pricing strategies, solidifies gene therapy's position as a pivotal element in the future landscape of retinal care, driving investment and research initiatives.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Value Chain Analysis
• Regulatory Bodies
• Pipeline Product Analysis
• Case Studies

Global Retinal Drugs Market Size by Drug Classes & CAGR (2026-2033)

• Market Overview
• Anti-VEGF Agents
  • VEGF-A Antagonists
  • Dual-target Anti-angiogenic Agents
• Corticosteroids
  • Intravitreal Implants
  • Injectable Suspensions
• Immunomodulators
• Gene & Cell Therapies
• Small Molecule Therapies
• Other Drug Classes

Global Retinal Drugs Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Macular Degeneration
• Diabetic Retinopathy
• Uveitis
• Others

Global Retinal Drugs Market Size by Formulation & CAGR (2026-2033)

• Market Overview
• Injectables (Solutions, Suspensions)
• Implants (Biodegradable, Non-biodegradable)
• Eye Drops
• Oral Tablets/Capsules
• Ointments & Gels

Global Retinal Drugs Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Retinal Drugs Market Size & CAGR (2026-2033)

• North America (Drug Classes, Indication, Formulation, Distribution Channel)
  • US
  • Canada
• Europe (Drug Classes, Indication, Formulation, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Classes, Indication, Formulation, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Classes, Indication, Formulation, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Classes, Indication, Formulation, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Roche Holding AG (incl. Genentech)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan (AbbVie Inc.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alcon Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Pharmaceutical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MeiraGTx Holdings plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocuphire Pharma, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kodiak Sciences Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adverum Biotechnologies, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oxurion NV
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Graybug Vision, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Clearside Biomedical, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Outlook Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iveric Bio (acquired by Astellas Pharma)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz (a Novartis spin-off for biosimilars)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coherus BioSciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations